Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers, bringing transformative therapies to patients with mTOR pathway driver alterations. Aadi has initiated PRECISION 1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivation alterations.